Research Article

Clinical Effect of Revascularization Strategies and Pharmacologic Treatment on Long-Term Results in Patients with Advanced Peripheral Artery Disease with TASC C and D Femoropopliteal Lesions

Table 5

Multivariate Cox regression analysis of primary patency in the two groups.

VariableMultivariate (EVT group)Multivariate (bypass group)
HR (95% CI) valueHR (95% CI) value

hsCRP (mg/L)1.02 (0.54–1.92)0.961.96 (0.77–5.0)0.157
Neuropathy0.83 (0.38–1.82)0.6480.89 (0.29–2.71)0.832
Statin treatment (yes/no)0.74 (0.38–1.45)0.3810.59 (0.25–1.42)0.241
Cilostazol treatment (>3 Ms/≤3 Ms)0.46 (0.26–0.82)0.0090.33 (0.15–0.75)0.008
Insulin alone (yes/no)0.98 (0.46–2.09)0.9662.72 (0.94–7.87)0.065
DR/IR0.43 (0.22–0.81)0.0090.5 (0.2–1.23)0.132

HR, hazard ratio; CI, confidence interval; DR, direct revascularization; EVT, endovascular therapy; hsCRP: high-sensitivity C-reactive protein; HA1c: hemoglobin A1c; IR, indirect revascularization.